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ABSTRACT
Tetracyclines have anticancer properties in addition to their well-known 
antibacterial properties. It has been proposed that tetracyclines slow metastasis and 
angiogenesis through inhibition of matrix metalloproteinases. However, we believe 
that the anticancer effect of tetracyclines is due to their inhibition of mitochondrial 
protein synthesis, resulting in a decrease of the mitochondrial energy generating 
capacity. Several groups have developed analogs that are void of antibacterial action. 
An example is COL-3, which is currently tested for its anticancer effects in clinical 
trials. We have undertaken a comparative study of the tetracycline analogs COL-3 
and doxycycline, which has an antibacterial function, to further investigate the role 
of the mitochondrial energy generating capacity in the anticancer mechanism and, 
thereby, evaluate the usefulness of mitochondria as an oncotarget. Our experiments 
with cultures of the human A549, COLO357 and HT29 cancer cells and fibroblasts 
indicated that COL-3 is significantly more cytotoxic than doxycycline. Mitochondrial 
translation assays demonstrated that COL-3 has retained its inhibitory effect on 
mitochondrial protein synthesis. Both drugs caused a severe decrease in the levels 
of mitochondrially encoded cytochrome-c oxidase subunits and cytochrome-c oxidase 
activity. In addition, COL-3 produced a marked drop in the level of nuclear-encoded 
succinate dehydrogenase subunit A and citrate synthase activity, indicating that COL-3 
has multiple inhibitory effects. Contrary to COL-3, the anticancer action of doxycycline 
appears to be based specifically on inhibition of mitochondrial protein synthesis, 
which is thought to affect rapidly proliferating cancer cells more than healthy tissue. 
Doxycycline is likely to cause less side effects that COL-3.
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INTRODUCTION
Tetracyclines are antibiotics that inhibit bacterial 
protein synthesis by binding to the small ribosomal 
subunit and blocking the attachment of aminoacyl-
tRNAs to the A site on the ribosome. Tetracyclines 
have an octahydronaphtacene structure consisting of 
four fused rings (Figure 1). The two long edges of this 
skeleton show a notable difference in the distribution of 
polar groups, producing a preference for hydrophobic 
interactions on one face and for hydrogen bonding on the 
other. This spatial arrangement is believed to be essential 
for the interaction with the small ribosomal subunit [1]. 
Doxycycline (DC; Figure 1) is one of the most commonly 
prescribed tetracycline derivatives. It is an inexpensive and 
safe drug, in use for more than 50 years to treat or prevent 
bacterial infections. It has optimal pharmacokinetic 
properties in humans and produces no bacterial resistance 
at a contra-indicative rate [2]. 
The potential use of tetracyclines in cancer therapy 
was first proposed in the 1980’s [3]. This proposal was 
based on the notion that mitochondrial ribosomes are 
           Research Paper
Oncotarget33819www.oncotarget.com
evolutionarily related to bacterial ribosomes, whereas 
eukaryotic cytosolic ribosomes are evolutionary related 
to archeal ribosomes. The suggestion was supported by 
experiments with various cancer cell cultures and animal 
models, which demonstrated that tetracyclines exhibit 
anticancer properties. The effects were attributed to an 
inhibition of mitochondrial protein synthesis, which lead to 
a decrease of the mitochondrial energy generating capacity 
in proliferating cells and result in a proliferation arrest in 
the G1 phase of the cell cycle [4]. In later years, several 
other mitochondrial changes were reported to be induced 
by tetracyclines in tumor cells, including cytochrome-
c-driven apoptosis, and a decrease in mitochondrial 
DNA-encoded proteins, respiration and inner membrane 
potential [5–9]. The postulated underlying bioenergetic 
mechanisms were reviewed recently [10]. 
Others have suggested that tetracyclines exert 
anticancer effects through their ability to chelate 
divalent cations, a property that is thought to inhibit 
matrix metalloproteinases (MMPs) that use zinc ions as 
a co-factor [11]. This led to the development of several 
new, chemically modified tetracyclines that lack the 
dimethylamino group considered crucial for the interaction 
with bacterial ribosomes, thus avoiding disruption of the 
gastrointestinal microbiota [12–15]. The most frequently 
studied tetracycline analogue void of antibacterial action 
is COL-3 (Figure 1). In vitro studies and work in animal 
models suggested that that COL-3 prevented, or at least 
restricted, metastasis and angiogenesis [16, 17]. COL-3 
has also been tested in Phase I and II clinical trials with 
patients suffering from Kaposi sarcoma [18, 19], recurrent 
high-grade gliomas [20], and from various other advanced 
malignancies and refractory metastatic cancers [21, 22]. 
COL-3 is FDA-approved for chronic inflammatory 
periodontal and skin diseases [23]. The trials and 
approvals were all based on the claimed inhibitory effect 
of COL-3 on the activity of MMPs in tumor or inflamed 
stroma. Unfortunately, actual measurements of MMP 
Figure 1: Chemical structures of tetracycline, and its analogs doxycycline and COL-3.
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enzyme activity were not performed in these studies. 
MMP activity assays were carried out in patients with 
abdominal aortic aneurysm treated with DC but failed to 
show differences compared to the untreated patient group 
[24]. In addition, the effects of any of the new, chemically 
modified tetracyclines on mitochondrial protein synthesis 
have not been investigated. We have argued that the 
serum and tissue levels of tetracycline analogs obtained 
with standard medication will not be sufficient to affect 
MMPs. Instead, we think that the obtained results should 
be interpreted to be caused by inhibition of clonal cell 
proliferation [25, 26]. 
It has been reported that COL-3 not only induces 
apoptosis but also necrosis [5, 27], a property not 
described for DC at therapeutic concentrations. In addition, 
leukopenia and thrombocytopenia were observed as side 
effects in a Phase I trial with COL-3 [22]. These adverse 
reactions and the fact that data on the effects of COL-3 
on the expression of mitochondrially synthesized proteins 
are still lacking, prompted us to compare COL-3 with DC 
systematically in cell culture systems. Our experiments 
show that DC specifically affects mitochondrially encoded 
translation products, whereas COL-3 acts as a nonspecific 
inhibitor, affecting mitochondrially encoded proteins as 
well as nuclear-encoded proteins. DC remains the optimal 
choice for a tetracycline-based chemotherapy due to its 
more selective mitochondria-based mechanism of action.
RESULTS
Experimental outlay
First, we compared the cytotoxicity of COL-3 and 
DC after 5 days of treatment of human cell cultures in 
viability dose-response curves. This was followed by a 
comparison of the proliferation of cell cultures treated with 
a single concentration of the drugs over a 5-day period 
in time course cell growth curves. Next, we investigated 
the effect of the drugs on de novo mitochondrial protein 
synthesis, followed by an assessment of the levels and 
enzymatic activity of several mitochondrial proteins over 
a 5-day treatment period. Finally, we investigated whether 
cells treated with the drugs showed evidence of apoptosis.
Cytotoxicity of COL-3 and DC
The cytotoxicity of COL-3 and DC was compared 
in human cell cultures treated for 5 days with vehicle 
(DMSO) or serial dilutions of the drugs. We evaluated 
the A549 lung adenocarcinoma, the COLO357 pancreatic 
adenocarcinoma and the HT29 colon adenocarcinoma cell 
lines, and used primary fibroblast cultures as controls. 
The viability dose-response curves shown in Figure 2 
clearly demonstrate that COL-3 is considerably more 
cytotoxic than DC. Toxicity for COL-3 is already apparent 
at concentrations that may be reached in clinical studies 
[20, 22]. The concentrations of the drugs resulting in a 
50% growth inhibition over the 5-day treatment period are 
given in Table 1. The toxicity of COL-3 is 12 to 40-fold 
higher than DC. Intriguingly, HT29 cells were 6.0-fold 
more resistant to DC but only 1.8-fold more resistant to 
COL-3, compared to A549 cells. Fibroblasts were 2.6-fold 
more resistant to DC but about equally sensitive to COL-3 
as A549 cells. 
A549 cell proliferation in presence of COL-3 or 
DC
To look at the effect of the drugs on cell proliferation 
over a 5-day treatment period in more detail, we treated 
A549 cell cultures with 8.1 µM (3 μg/ml) of COL-3 or 
19.5 µM (10 μg/ml) of DC or vehicle for 1 to 5 days and 
determined cell numbers each day. The concentrations 
of the drugs were chosen so that they correspond to 
the expected serum levels of COL-3 and DC in vivo in 
patients treated with the standard recommended dose 
[20, 22, 28, 29]. Results of the time course experiment 
are shown in Figure 3A. A549 cells treated with vehicle 
show logarithmic growth with a doubling time of 23.1 
hour. The drugs have no effect on the cell proliferation 
rate after 1 day of treatment (approximately 1 doubling 
time) but further treatment with COL-3 halts proliferation 
completely and results in massive cell death during the 
final day of treatment. In contrast, further treatment with 
DC does not halt but slows the proliferation, especially 
after day 2 (approximately 2 doubling times). Thus, cells 
cultured in the presence of COL-3 show a lag phase of 1 
doubling time before they respond to the drug, whereas 
cells cultured in the presence of DC show a lag phase of 
about 2 doubling times. Microscopic examination of the 
A549 cells after 5 days of treatment (Figure 3B) confirmed 
the slower growth of the cells treated with DC and 
revealed some cells in the process of dying. Five days of 
treatment with COL-3 resulted in a very sparse population 
of dying cells (Figure 3B). 
De novo mitochondrial protein synthesis in 
presence of COL-3 or DC
As outlined in the introduction, we believe that the 
in vivo anticancer effect of DC is based on its inhibition of 
mitochondrial protein synthesis. We therefore compared 
the effect of COL-3 and DC on mitochondrial translation. 
For this purpose, A549 cell cultures were treated with 
8.1 µM of COL-3 or 19.5 µM DC or vehicle for 1 h 
before and during a 1-h labeling with [35S]-methionine 
in the presence of emetine to inhibit cytosolic protein 
synthesis. Autoradiography of samples resolved by gel 
electrophoresis clearly revealed radioactive labeling of 
the 13 polypeptides encoded by mitochondrial DNA 
(Figure 4A). In addition, the autoradiographs showed 
that both drugs resulted in a general decrease of the 
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de novo mitochondrial protein synthesis. Quantification of 
the radioactive signals of the co-migrating cytochrome-c 
oxidase subunits II and III (MTCO2 + MTCO3) from four 
independent experiments showed that the two drugs result 
in a similar decrease of mitochondrial protein synthesis of 
~27% compared to vehicle-treated cells (Figure 4B). 
The effect of COL-3 and DC on mitochondrial 
protein expression
To investigate the specificity of the two drugs in 
more detail, we determined the levels of a number of 
mitochondrial proteins by western blot in A549 cells. 
The treatment protocol and chosen drug concentrations 
were identical to those of the time course proliferation 
study as shown in Figure 3. The western blots revealed 
that DC treatment resulted in a steady decrease of the two 
mitochondrially synthesized subunits of cytochrome-c 
oxidase MTCO1 and MTCO2 over the 5-day treatment 
period to ~12% of control values. COL-3 treatment also 
resulted in a steady decrease, but the decline was not as 
strong as for DC (Figure 5A–5C). As anticipated, DC 
treatment had no effect on the levels of subunit A of 
succinate dehydrogenase (SDHA), which is synthesized in 
the cytosol; however, unexpectedly, 5-day treatment with 
COL-3 led to a 68% reduction of SDHA levels (Figure 5A, 
5D). We also determined the levels of the mitochondrial 
outer membrane protein TOMM20 in surviving cells. 
This protein is synthesized in the cytosol and is a good 
indicator of the amount of mitochondria. Both DC and 
COL-3 treatment had no statistically significant effect 
on TOMM20 levels, suggesting that the total amount of 
mitochondria is not affected by the drugs (Figure 5A, 5E). 
The effect of COL-3 and DC on mitochondrial 
enzyme activity
To investigate the functional implications of the 
decreased mitochondrial protein synthesis, we compared 
the effect of the two drugs on the activity of two 
mitochondrial enzymes: the respiratory chain enzyme 
cytochrome-c oxidase, which contains three subunits 
synthesized in mitochondria [30], and the Krebs cycle 
enzyme citrate synthase, which is constituted entirely of 
subunits synthesized in the cytosol. Again, the treatment 
protocol and chosen drug concentrations were identical to 
those in the time course proliferation study. The enzyme 
activity measurements revealed that both COL-3 and 
Figure 2: COL-3 is more cytotoxic than DC. Viability dose-response curves of cultured fibroblasts, and the A549, COLO357 and 
HT29 cancer cell lines treated with doxycycline or COL-3 for 5 days. Experiments were performed in quadruplicate. Results are shown as 
mean percentage of surviving cells relative to vehicle-treated cells ± standard deviation. 
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DC have a similar, strong effect on the cytochrome-c 
oxidase activity (Figure 6A). After ≥3 days of treatment, 
the activity is only ~20% of that of the vehicle-treated 
cells. As expected, DC did not have any effect on citrate 
synthase activity but, remarkably, COL-3 treatment 
resulted in a >40% decrease in activity after ≥3 days of 
treatment (Figure 6B). 
Do COL-3 and DC cause apoptosis?
The time course experiments (Figure 3A) showed 
that COL-3 stops cell proliferation after 1 day of treatment 
and results in massive cell death at day 5, whereas DC 
slows down cell proliferation after 2 days of treatment 
but does not result in massive cell death. To investigate 
if the drugs cause apoptosis, we determined the levels of 
procaspase 3 and active (cleaved) caspase 3 over a 5-day 
treatment period on western blots. As a positive control, 
we used a sample of cultured A549 cells treated with 
the alkaloid staurosporine, which is known to induce 
apoptosis. Unlike in the staurosporine-treated cells, we 
observed no decrease in procaspase 3 levels in the COL-
3 and DC-treated cells and, importantly, we did not 
detect cleaved caspase 3 over the 5-day treatment period 
(Figure 7). Because (cleaved) caspase 3 is the master 
coordinator of the destruction of cellular structures during 
apoptosis, the results indicate that neither COL-3 nor DC 
induce apoptosis. The massive cell death seen in COL-3-
Table 1: Drug concentrations resulting in a 50% growth inhibition over a 5-d culture period
Cell culture 50% Growth inhibition





Figure 3: DC decreases the proliferation rate of A549 cells, whereas COL-3 kills A549 cells after 5 d of treatment. 
(A) Time course proliferation curves of A549 cells treated with vehicle, 19.1 µM doxycycline, or 8.1 µM COL-3 over a 5-day time 
period. Experiments were performed in quadruplicate. Results are shown as mean number of cells ± standard deviation. Asterisks denote 
statistically significant differences compared to vehicle-treated cells (p < 0.05). (B) Micrographs of A549 cell cultures treated with vehicle, 
19.1 µM doxycycline or 8.1 µM COL-3 for 5 d. Arrows indicate dying cells. Scale bar: 100 μm.
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treated cells is, therefore, likely to be the result of necrosis. 
This is further supported by the absence of apoptotic 
bodies at day 5 (Figure 3B).
DISCUSSION
The results of this study clearly confirmed that 
the main mode of action of DC is its inhibition of the 
expression of mitochondrially encoded translation 
products. These proteins are indispensable for oxidative 
phosphorylation and, thus, the mitochondrial energy 
generating capacity. In proliferating cells, this process 
can be inhibited without interfering with the expression 
of the nuclear-coded genetic information. In contrast, 
COL-3 appears to affect almost every aspect that we 
have investigated, including the mitochondrial protein 
synthesis, the levels of mitochondrially encoded (MTCO1 
and MTCO2) as well as nuclear encoded (SDHA) 
proteins, and the activity of cytochrome-c oxidase, which 
contains mitochondrially synthesized subunits, as well 
as citrate synthase, which is composed solely of subunits 
synthesized in the cytosol. Structural differences between 
DC and COL-3 may alter other cellular mechanisms of 
toxicity, e.g. the assembly or function of the spliceosome 
[31], which is structurally similar to the ribosome. 
Tetracyclines may also alter gene splicing by directly 
interacting with pre-mRNA [31]. Subtle-differences in 
structure-activity relationships among tetracycline analogs 
may explain observed differences in the cell-specific 
cytotoxicity of COL-3 and the mechanism by which it 
alters the expression of nuclear encoded proteins like 
SDHA and citrate synthase. 
In the viability dose-response experiments, 5-d 
treatment of A549 cells with 8.1-µM COL-3 resulted 
in a ~26% decrease of cells compared to untreated cells 
(Figure 2), whereas this treatment resulted in a complete 
collapse of the culture in the proliferation time course 
experiments (Figure 3A). The cytotoxicity of 19.1 µM 
DC also appeared less in the dose-response than in the 
time course experiments with A549 cells. In the dose-
response experiments, cells were cultured in 96-well plates 
to allow the measurement of the effect of a large number 
of drug concentrations, while cells were cultured in 10-cm 
plates in the time course experiments to permit the parallel 
determination of cell number (Figure 3A), protein level 
(Figures 5, 7) and enzyme activity (Figure 6). Apparently, 
these different experimental set-ups affect the cytotoxicity 
of the drugs. 
A 5-day treatment of A549 cells with DC or COL-3 
caused a striking decrease of the mitochondrially encoded 
cytochrome-c oxidase subunits MTCO1 and MTCO2, 
and cytochrome-c oxidase activity to 11–28% of control 
values, whereas a 2-h treatment with the drugs resulted in 
a relatively modest fall in de novo mitochondrial protein 
synthesis to ~73% of control values (Figures 4–6). It may 
seem that this reduction in mitochondrial protein synthesis 
is too small to explain the dramatic decreases in MTCO1 
and MTCO2 levels, and cytochrome-c oxidase activity but 
we expect that longer treatment with the drugs will lead to 
a larger drop in mitochondrial protein synthesis. 
Figure 4: DC and COL-3 decrease mitochondrial translation. (A) De novo mitochondrial protein synthesis of A549 cells treated 
with vehicle, 19.1 µM doxycycline, or 8.1 µM COL-3. Cells were pre-treated with the drugs for 1 hour, followed by a 1-hour pulse labeling 
with [35S]-methionine in the presence of the drugs and emetine to block cytosolic protein synthesis. Denatured, 30-μg protein samples were 
subjected to 12% acrylamide gel electrophoresis. The gel was stained with Coomassie to verify even loading, followed by autoradiography 
to reveal the labeled mitochondrial translation products, indicated on the left. The migration of protein standards is indicated in the 
center. (B) Mean MTCO2 + MTCO3 labeling signals of the drug-treated cells relative to the mean value of vehicle-treated cells of four 
independent experiments. Error bars indicate standard deviation. Asterisks denote statistically significant differences (p < 0.05).
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Figure 5: DC decreases the levels of mitochondrially synthesized proteins, whereas COL-3 decreases the levels of 
mitochondrially as well as cytosolically synthesized proteins. (A) Western blot image of denatured, 10-μg protein samples 
from A549 cells treated with vehicle, 19.1 µM doxycycline, or 8.1 µM COL-3 over a 5-day time period and subjected to 4–20% gel 
electrophoresis. The blot was developed with antibodies raised against SDHA, MTCO1, MTCO2, TOMM20 and β-actin as loading control. 
The migration of a protein standard marker (M) is indicated on the right. (B−E) Mean MTCO1 (B), MTCO2 (C), SDHA (D) and TOMM20 
(E) signals in the treated cells over a 5-day time period, relative to the signal of cells at t = 0 in four independent experiments. Error bars 
indicate standard deviation. Asterisks denote statistically significant differences from vehicle-treated cells (p < 0.05).
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The doubling time of the three cancer cell lines 
that we investigated is very similar under untreated, basal 
growth conditions (~24 h). We found that HT29 cells are 
more resistant to the drugs than A549 cells, especially to 
DC (Figure 2; Table 1). We assume that HT29 cells are not 
necessarily less sensitive to the anti-mitochondrial action 
of DC but that the antibiotic is imported less efficiently 
into the cells, or is eliminated more efficiently. The 
increased resistance of fibroblast to DC compared to A549 
cells is expected in view of their longer doubling time of 
43 h, resulting in a slower decrease of mitochondrially 
synthesized proteins through cell division. In contrast, 
fibroblasts and A549 cells are similarly sensitive to COL-
3, suggesting that the toxicity of COL-3 involves an 
active mechanism in addition to the passive dilution of 
mitochondrially synthesized proteins through cell division.
The lag phase
As shown in the viability dose-response curves 
(Figure 2), cell proliferation is less inhibited by DC than 
by COL-3 at moderate molarity. Proliferation time course 
experiments (Figure 3A) revealed that the lag phase, 
before an effect of 19.5 µM DC on the proliferation rate of 
A549 cells becomes apparent, is 2 days. By then, the levels 
of both the mitochondrially synthesized cytochrome-c 
oxidase subunits and cytochrome-c oxidase activity have 
decreased to about one-third of normal levels (Figures 
5A–5C and 6). Apparently, at this point, the mitochondrial 
energy generating capacity is too low to sustain normal 
cell growth and, consequently, the proliferation rate drops. 
Although longer treatment with DC results in a further 
decrease of the mitochondrially synthesized subunits and 
cytochrome-c oxidase activity, the proliferation does not 
come to a complete halt within the 5-day time frame. This 
suggests that under the in vitro culturing conditions, the 
cells are still able to generate sufficient energy to sustain 
some proliferation. A somewhat stronger inhibition of the 
proliferation rate has been obtained by Onoda et al. [5], 
who performed cytotoxicity studies over a 2-d time period. 
Several groups have observed that cells treated with DC 
accumulate in the G1 phase of the cell cycle, prior to the 
S phase when the bulk of the building blocks for cell 
division are synthesized [4, 7, 32–34]. This is compatible 
with the idea that insufficient mitochondrial energy supply 
reduces the proliferation rate by impeding the synthesis of 
macromolecules. 
The lag phase of 8.1-µM COL-3 treatment of A549 
cells is only 1 day, which corresponds to the observation 
by Song et al. [8]. After 1 day of COL-3 treatment, 
proliferation of A549 cells completely stops. Also for 
COL-3, a modest arrest in G0/G1 has been reported in 
a short-term experiment [35]. This is in line with our 
observation of decreased mitochondrially synthesized 
protein levels and cytochrome-c oxidase activity. The 
much shorter lag phase and complete growth arrest by 
COL-3 may be explained by the fact that COL-3 causes 
a much broader spectrum of effects than DC, resulting 
not only in defects of mitochondrially synthesized cell 
components but also in cytosolically synthesized cell 
components, such as succinate dehydrogenase and citrate 
synthase. The longer lag phase seen in DC-treated cells 
strongly supports our view that the proliferation arrest 
occurs secondary to the inhibition of mitochondrial 
protein synthesis. It is also the basis for our opinion that 
mitochondria are a prime oncotarget. The usefulness of DC 
is based on the fact that normal tissues do not suffer from 
serious side effects because they are either post-mitotic 
or their proliferation rate tends to be relatively slow, their 
mitochondrial content is plentiful and they have ample 
mitochondrial energy generating capacity. This view is 
supported by the observed diminished DC cytotoxicity 
Figure 6: DC decreases the activity of cytochrome-c oxidase, whereas COL-3 decreases the activity of cytochrome-c 
oxidase as well as citrate synthase. Cytochrome-c oxidase (A) and citrate synthase (B) activity in A549 cells treated with vehicle, 19.1 
µM doxycycline, or 8.1 µM COL-3 over a 5-day time period. Assays were performed in quadruplicate. Results are shown as mean value ± 
standard deviation. Asterisks denote statistically significant differences from vehicle-treated cells (p < 0.05).
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of primary fibroblast cultures compared to the A549 
and COLO357 cell lines (Table 1). Notable exceptions 
to the slow proliferation of normal cells are the rapidly 
dividing hemopoietic stem and progenitor cells. However, 
tetracyclines do not appear to affect the proliferation of 
these cells from the bone marrow. Long-term continuous 
treatment of rats with oxytetracycline by intravenous 
transfusion revealed that the animals restored their anemia 
after bleeding as quickly as controls transfused with 
vehicle. Effects of oxytetracycline on immune responses 
were only found for events related to T-cell proliferation, 
not B-cell proliferation [36]. Apparently, the resistance 
of T-cells is changed during their passage through the 
thymus. In their recent publication, Pulvino et al. [37] 
report a cytostatic effect on doxycycline on diffuse large 
B-cell lymphoma and other non-Hodgkin lymphomas. 
Perhaps these cells underwent genetic changes during their 
oncogenic transformation that reversed their resistance to 
tetracyclines. 
Is there a need for tetracycline analogs void of 
antibacterial activity?
The claimed necessity for tetracycline analogs 
as anticancer drugs that are void of antibacterial 
activity underlies the development of chemically 
modified tetracyclines [11]. However, sound scientific 
considerations or experimental and medical evidence for 
Figure 7: Absence of active cleaved caspase 3 indicates that DC and COL-3 do not induce apoptosis. (A) Western blot 
image of denatured, 10-μg protein samples from A549 cells treated with vehicle, 19.1 µM doxycycline, or 8.1 µM COL-3 over a 5-day time 
period and subjected to 12% gel electrophoresis. A549 cells treated with 1 µM staurosporine (Stau.) for 3 h served as an apoptosis positive 
control sample. The blot was sequentially developed with antibodies raised against caspase 3 and β-actin as loading control. The migration 
of a protein standard marker is indicated on the right. (B) Mean procaspase 3 signals in the treated cells, relative to the signal of cells at t 
= 0 in three independent experiments. Error bars indicate standard deviation. 
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this opinion are lacking. DC does not appear to provoke 
a serious resistance problem for the human microbiome. 
In fact, DC is seldom mentioned in publications were 
resistance data of tetracyclines are compared. Bartlett 
et al. [38] reported that tetracycline increases the 
occurrence of resistant Escherichia coli by 1000-fold in 
the fecal flora, compared to DC. The pharmacokinetic 
properties of DC are in this respect advantageous; at oral 
application, the rapid rise of serum levels indicates that the 
antibiotic is largely absorbed by the small intestine and, 
thus, DC represents a low burden for the colorectal tract, 
the main reservoir of gut microbes. Serious side effects of 
DC are also uncommon. Phototoxicity is mentioned as a 
side effect of DC. Treatments are, therefore, sometimes 
combined with a sunblock, although simply refraining 
from direct sunlight will suffice. Hyperpigmentation [39, 
40] and photo-onycholysis [41] are reported sporadically 
but, altogether, there is little reason to exclude DC as a 
potential drug in the fight against cancer. 
Our experiments show that COL-3 has kept the 
inhibitory effect on mitochondrial protein synthesis. For 
this reason, the loss of antibacterial properties of COL-
3 cannot be attributed to the principle mode of action of 
tetracyclines at the level of protein synthesis. Most likely, 
the loss of antibacterial effects of COL-3 is based on its 
impermeability of the bacterial cell walls. The available 
evidence leads to the conclusion that DC is far more 
preferable than COL-3 to treat cancer, either on its own or 
in combination therapy. Clinical trials with COL-3 should 
be discouraged or, at least, be performed double-blind DC-
controlled, rather than placebo-controlled. 
MATERIALS AND METHODS
Cell culturing
A primary human dermal fibroblast culture was 
established from a skin explant of a 69-year-old male 
control subject after informed written consent, according 
to standard procedures. Ethical approval for this work 
was obtained from the Royal Free Hospital and Medical 
School Research Ethics Committee (REC 07/H0720/161). 
Fibroblasts, A549 human alveolar adenocarcinoma [42], 
COLO357 human pancreatic adenocarcinoma [43] and 
HT29 human colon epithelium adenocarcinoma [44] cell 
lines were all cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing GlutaMAX™ and 4.5 g 
of glucose/l (Gibco Lifetechnologies, Cat. No.: 61965–
029), and supplemented with 10% fetal bovine serum, 1 
mM sodium pyruvate, 50 μg/ml of uridine, 50 units/ml 
of penicillin and 50 μg/ml of streptomycin at 37° C in 
a humidified atmosphere of 5% CO2 in 95% air, unless 
stated otherwise. The cancer cell lines were obtained from 
the European Collection of Authenticated Cultures and 
used for the experiments within two weeks after receipt.
Determination of cytotoxicity after 5 days of 
treatment
To examine the cytotoxicity of DC and COL-3, 
cells were seeded in the wells of black Corning 96-well 
CellBIND® assay plates with clear flat bottoms (Cat. 
No.: 3340) at an empirically derived density that would 
allow logarithmic cell growth over a 6-day time period. 
The next day, medium was changed and cells were treated 
with serial dilutions of DC, COL-3 or vehicle (dimethyl 
sulfoxide, DMSO), using stock solutions of 50 mM 
doxycycline hyclate (Sigma, Cat. No.: D-9891) in water 
and 20 mM COL-3 (trade name: Metastat; synonyms: 
CMT-3, 4-dedimethylaminosancycline, 6-demethyl-
6-deoxy-4-dedimethylaminotetracycline; incyclinide; 
Echelon, Cat. No.: B-0802) in DMSO. Stocks were 
protected from light and stored at −20° C. Treatment 
was repeated each day over a 5-day time period. After 
the 5-day treatment, medium was removed and plates 
were frozen at −20° C. The number of cells per well 
was determined with the CyQUANT® Cell Proliferation 
Assay Kit (ThermoFisher Scientific, Cat. No.: C7026), 
which measures the DNA content in a fluorescent assay 
on a plate reader. Cell numbers were calculated with the 
help of parallel measurements of serial dilutions of cell 
suspensions with a known cell concentration determined 
by trypan blue exclusion cell counting on C-Chip 
hemocytometer slides (NanoEnTek, Cat. No: DHC-N01). 
Experiments were carried out in quadruplicate and 
expressed as percentage of the number of cells in vehicle-
treated wells.
Determination of cell proliferation over 5 days of 
treatment
To assess the effect of DC and COL-3 on A549 
cell proliferation over a 5-day treatment period, 1.0 × 
104 A549 cells were seeded on 10-cm tissue culture 
dishes (Sarstedt, Cat. No.: 83.3902). This seeding density 
allows logarithmic growth over a 6-day time period. The 
next day, medium was removed and cells were treated 
with 19.5 µM DC (10 μg DC per ml of medium), 8.1 
µM COL-3 (3 μg COL-3 per ml of medium) or vehicle 
(0.4 µl DMSO per ml of medium) in fresh medium. 
Treatment was repeated each day over a 5-day time 
period, but every day dishes were chosen randomly to 
determine the number of cells per plate. Cells on these 
plates were dislodged by trypsinization, collected by 
centrifugation, resuspended and counted on C-Chip 
hemocytometer slides. Experiments were performed in 
quadruplicate with independent samples and expressed as 
absolute cell number. The population doubling time (DT) 
was calculated using the formula DT = (t-t0)log2/(logN-
logN0), where t and t0 are the times at which the cells were 
counted, and N and N0 are the cell numbers at these times. 
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After 5 d of treatment, cell cultures were examined 
under an Olympus CK2 phase contrast microscope at 
200× magnification. Images were captured with a Zeiss 
Axiocam MRm camera and were processed with Adobe® 
Photoshop® software.
Labeling of mitochondrial translation products
To examine the effect of the drugs on de novo 
mitochondrial protein synthesis, A549 cells were cultured 
in wells of a Sarstedt 6-well cell culture plate (Cat. No.: 
83.3920) until 80% confluency was reached. Then, cells 
were washed three times for 10 min with methionine 
and cysteine deficient DMEM (Gibco Lifetechnologies, 
Cat. No.: 21013–024), supplemented with 19.5 µM DC, 
8.1 µM COL-3 or vehicle. Next, cells were incubated in 
methionine and cysteine deficient DMEM, supplemented 
with 0.5 mM L-cysteine, 2 mM L-glutamine, 1 mM 
sodium pyruvate, 5% dialyzed fetal bovine serum, and 19.5 
µM DC, 8.1 µM COL-3 or vehicle for 10 min. Emetine 
dihydrochloride hydrate (Sigma, Cat. No.: E2375) was 
added to a final concentration of 100 μg per ml of medium 
and cells were incubated for a further 20 min. L-[35S]-
Methionine (Perkin Elmer, Cat. No.: NEG009L010MC) 
was added to a final concentration of 5.3 MBq per ml of 
medium and cells were incubated for an additional 1 h. 
After 1 h, medium was removed, and cells were rinsed 
with phosphate-buffered saline (PBS) and dislodged with 
trypsin. Trypsinization was stopped with standard DMEM 
culture medium, and cells were collected by centrifugation 
at 1000 × g for 5 min. The cell pellet was washed once 
with PBS and then lysed with 0.1% n-dodecyl-β-D-
maltoside (Anatrace; Cat. No.: D310) in PBS, 1 mM 
phenylmethylsulfonyl, 1 µg/ml of leupeptin 1 µg/ml of 
pepstatin A and 10 µl/ml of Benzonase® nuclease solution 
(Sigma, Cat. No.: E1014) on ice for 15 min. Sodium 
dodecyl sulfate (SDS) was added to a final concentration 
of 1%, followed by a further 15-min incubation on ice. 
Then, samples were brought to room temperature to allow 
all SDS to dissolve and tubes were centrifuged at 12,000 × 
g for 5 min. The protein concentration of the supernatants 
was determined with the Pierce® BCA Protein Assay Kit 
(ThermoFisher Scientific, Cat. No.: 23225), according 
to the manufacturer’s microplate procedure. Samples of 
30 μg protein in 1× Laemmli Sample Buffer (BioRad, Cat. 
No.: 161–0747) and 1× NuPAGE Sample Reducing Agent 
(Lifetechnologies, Cat. No.: NP00009) were resolved 
by electrophoresis through NuPAGE 12% Bis-Tris 
Protein Gels (Lifetechnologies, Cat. No.: NP0341) with 
NuPAGE MES SDS Running Buffer (Lifetechnologies, 
Cat. No.: NP0002) alongside Precision Plus Protein™ 
Unstained Standards (BioRad, Cat. No.: 161–0373). After 
electrophoresis, gels were stained for 30 min with 0.25% 
Coomassie Brilliant Blue R-250 in 50% methanol and 
10% acetic acid. The gels were destained for 5 h in 50% 
methanol and 10% acetic acid, followed by equilibration 
in 30% methanol, 5% glycerol overnight. Gels were dried 
under vacuum for 3 h at 70° C, followed by exposure to 
CL-XPosure film (Thermoscientific, Cat. No.: 34090). 
Images of the stained gels and autorads were captured with 
the BioRad Chemidoc™ MP Imaging System. Signals 
were quantified with Image Lab 5.1 software (BioRad). 
Radioactive signals on the autorad were normalized with 
the aid of the total Coomassie staining signal of the gel 
lanes and expressed relative to the radioactive signal 
from cells treated with vehicle. The experiments were 
performed in quadruplicate with independent samples.
Determination of mitochondrial protein levels 
over 5 days of treatment
To evaluate the effect of DC and COL-3 on the 
expression of specific A549 mitochondrial proteins over a 
5-day treatment period, 1.0 × 104 A549 cells were seeded 
on 10-cm tissue culture dishes. The next 5 days, cells were 
treated daily with 19.5 µM DC, 8.1 µM COL-3 or vehicle, 
as described above for the time course proliferation assay. 
During the 5-day treatment, dishes were chosen randomly 
each day for harvesting of cells by trypsinization. Cells 
were collected by centrifugation in culture medium, 
washed twice with PBS and proteins were extracted with 
1% Triton X-100 in PBS, 1 mM phenylmethylsulfonyl, 
1 μg/ml of leupeptin and 1 μg/ml of pepstatin A on ice 
for 15 min. After centrifugation at 16,000 × g, 4° C, for 
10 min, the protein concentration in the supernatants 
was determined with the Pierce® BCA Protein Assay Kit. 
Supernatants were stored at -80° C and used within 1 
month. To prepare western blots, 10-μg protein samples 
in 1× Laemmli Sample Buffer and 1× NuPAGE Sample 
Reducing Agent were resolved on Criterion™ TGX Stain-
Free 4–20% precast gels (BioRad, Cat. No.: 5678094) 
alongside Precision Plus Protein™ Standards (BioRad, 
Cat. No.: 161–0374) and blotted onto Trans-Blot® Turbo™ 
0.2-μm PVDF membranes (BioRad, Cat. No.: 170–4157), 
using the BioRad Trans-Blot® Turbo™ Transfer System. 
Protein binding sites on the blots were saturated with 10% 
skimmed milk powder in PBS for 1 hour, followed by a 
rinse with PBS, 0.3% Tween-20 and primary antibody 
incubation in PBS, 0.3% Tween-20, at 4° C, overnight. 
A cocktail of the following antibodies were used: anti-
succinate dehydrogenase subunit A (SDHA; Abcam, 
Cat. No: ab14715), anti-cytochrome-c oxidase subunit I 
(MTCO1; Abcam, Cat. No.: ab140705), anti-cytochrome-c 
oxidase subunit II (MTCO2; Abcam, Cat. No.: ab110258), 
anti-translocase of outer mitochondrial membrane subunit 
20 (TOMM20; Santa Cruz Biotechnology, Cat. No.: sc-
11415) and anti-β-actin (Abcam, Cat. No.: ab6276). 
Excess of primary antibodies were removed with three 
10-min washes in PBS, 0.3% Tween-20, followed by 
a 1-h incubation with the horse radish peroxidase-
conjugated secondary antibodies goat anti-mouse IgG 
and goat anti-rabbit IgG (Dako, Cat. No.: P0447 and 
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P0448) in PBS, 0.3% tween-20, and another three 10-min 
washes. Blots were developed with Clarity™ Western 
ECL Substrate (BioRad, Cat. No.: 170–5060). Capturing 
of the chemiluminescent signals was performed with the 
BioRad Chemidoc™ MP Imaging System. Signals were 
quantified with Image Lab 5.1 software. Mitochondrial 
protein signals were normalized with the aid of the β-actin 
signal and expressed relative to the signal from cells at 
t = 0. The experiments were performed in quadruplicate 
with independent samples.
Determination of enzyme activities over 5 days of 
treatment
To investigate the effect of the drugs on A549 
cytochrome-c oxidase and citrate synthase activity over a 
5-day treatment period, 1.0 × 104 A549 cells were seeded 
on 10-cm tissue culture dishes. The next 5 days, cells were 
treated daily with 19.5 µM DC, 8.1 µM COL-3 or vehicle, 
and samples were collected exactly as described above 
for the western blot experiments. Proteins were extracted 
with 1.5% n-dodecyl-β-D-maltoside in PBS, 1 mM 
phenylmethylsulfonyl, 1 μg/ml of leupeptin and 1 μg/ml 
of pepstatin A on ice for 15 min [45]. After centrifugation 
at 16,000 × g, 4° C, for 10 min, supernatants were stored 
at −80° C. The stored supernatants were used in the assays 
within 10 days of storage. All assays were carried out in 
quadruplicate.
Cytochrome-c oxidase activity was determined 
spectrophotometrically at 30° C by monitoring the rate 
of ferrocytochrome-c oxidation of 50 µM horse heart 
ferrocytochrome-c in 10 mM KPi (pH 7.0) at 550 nm. The 
activity was calculated as the first-order velocity constant 
k [46]. Ferrocytochrome-c was prepared by reduction of 
1 g of horse heart (ferri)cytochrome-c (Sigma; Cat. No.: 
C7752) with 13 mg of L-ascorbic acid in 100 ml of 100 
mM KPi (pH 7.0), followed by extensive dialysis in 10 
mM KPi (pH 7.0) at 4° C, and was stored at −80° C. Citrate 
synthase activity was measured according to Srere [47] at 
30° C by monitoring the rate of 5-thio-2-nitrobenzoic acid 
formation of 100 µM 5,5′-dithiobis(2-nitrobenzoic acid) 
(Sigma, Cat. No.: D8130) in 100 mM Tris·HCl (pH 8.0), 
100 µM acetyl Co-enzyme A (Sigma, Cat. No.: A2056), 
100 µM oxaloacetic acid (Sigma, Cat. No.: O4126) and 
0.1% Triton X-100, using a plate reader at 412 nm. The 
protein concentration of the samples was determined with 
the Pierce® BCA Protein Assay Kit. 
Determination of caspase 3 levels over 5 days of 
treatment
To assess procaspase 3 and caspase 3 expression 
over a 5-day treatment period, the same samples as for the 
determination of mitochondrial protein levels were used. 
To obtain an apoptosis positive control sample, cultured 
A549 cells were treated with 1 µM staurosporine for 3 h, 
using a stock solution of 1 mM staurosporine (Sigma, 
Cat. No.: S4400) in DMSO. After treatment, cells were 
harvested and extracted with Triton X-100 as described 
above. Western blots were prepared as for the analysis of 
mitochondrial proteins, except that samples were resolved 
on Criterion™ TGX Stain-Free 12% precast gels (BioRad, 
Cat. No.: 568044). Protein binding sites on the blots were 
saturated with 1× Casein Blocking Buffer (Sigma, Cat. 
No.: B6429), followed by incubation with an anti-caspase 
3 antibody (Cell Signaling, Cat. No.: 9662) in the same 
buffer at 4° C, overnight. Further washings, secondary 
antibody incubation and chemiluminescent imaging were 
carried out as described above. The blots were re-probed 
with an anti-β-actin antibody (Sigma, Cat. No.: A2066). 
The procaspase 3 signal was normalized with the help of 
the β-actin signal and expressed relative to the signal from 
cells at t = 0. Experiments were performed in triplicate 
with independent samples.
Statistical analyses
All graphs and statistical analyses were executed 
with GraphPad Prism® version 6.01 software. As the 
sample size was too small to confirm normal distribution, 
we used non-parametric Kruskal-Wallis tests to examine 
statistical significance. Statistical significance levels were 
set to p < 0.05 with Bonferroni correction for multiple 
pairwise comparisons.
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